{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:20:10Z","timestamp":1791580810233,"version":"4.3.4"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","prd-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism & Related Disorders"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.parkreldis.2016.04.014","type":"journal-article","created":{"date-parts":[[2016,4,21]],"date-time":"2016-04-21T16:52:10Z","timestamp":1461257530000},"page":"41-48","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials"],"prefix":"10.1016","volume":"28","author":[{"given":"Jee","family":"Bang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iryna V.","family":"Lobach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony E.","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murray","family":"Grossman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Knopman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce L.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lon S.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachelle S.","family":"Doody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Lees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce H.","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam L.","family":"Boxer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2016.04.014_bib1","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S1474-4422(09)70042-0","article-title":"Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges","volume":"8","author":"Williams","year":"2009","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.parkreldis.2016.04.014_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/WNL.47.1.1","article-title":"Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop","volume":"47","author":"Litvan","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2016.04.014_bib3","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1002\/mds.26054","article-title":"The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases","volume":"29","author":"Respondek","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2016.04.014_bib4","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1055\/s-0034-1381739","article-title":"Clinical trials: past, current, and future for atypical parkinsonian syndromes","volume":"34","author":"Tsai","year":"2014","journal-title":"Semin. Neurol."},{"key":"10.1016\/j.parkreldis.2016.04.014_bib5","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1093\/brain\/awn291","article-title":"Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study","volume":"132","author":"Bensimon","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.parkreldis.2016.04.014_bib6","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/S1474-4422(14)70088-2","article-title":"Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2\/3 trial","volume":"13","author":"Boxer","year":"2014","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.parkreldis.2016.04.014_bib7","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/mds.25824","article-title":"A\u00a0phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy","volume":"29","author":"Tolosa","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2016.04.014_bib8","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1093\/brain\/awm032","article-title":"A\u00a0clinical rating scale for progressive supranuclear palsy","volume":"130","author":"Golbe","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.parkreldis.2016.04.014_bib9","series-title":"Third Symposium on Parkinson's Disease Research","first-page":"152","article-title":"Projecton technique for evaluating surgery in Parkinson's disease","author":"Schwab","year":"1969"},{"issue":"2","key":"10.1016\/j.parkreldis.2016.04.014_bib10","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1097\/00002093-199700112-00004","article-title":"Validity and reliability of the Alzheimer's disease cooperative study-clinical global impression of change. The Alzheimer's disease cooperative study","volume":"11","author":"Schneider","year":"1997","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"10.1016\/j.parkreldis.2016.04.014_bib11","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1076\/jcen.20.3.310.823","article-title":"The repeatable battery for the assessment of neuropsychological status (RBANS): preliminary clinical validity","volume":"20","author":"Randolph","year":"1998","journal-title":"J.\u00a0Clin. Exp. Neuropsychol."},{"key":"10.1016\/j.parkreldis.2016.04.014_bib12","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0022-3956(82)90033-4","article-title":"Development and validity of a geriatric depression scale: a preliminary report","volume":"17","author":"Yesavage","year":"1983","journal-title":"J.\u00a0Psychiatr. Res."},{"issue":"8","key":"10.1016\/j.parkreldis.2016.04.014_bib13","doi-asserted-by":"crossref","first-page":"e22293","DOI":"10.1371\/journal.pone.0022293","article-title":"Disease severity and progression in progressive supranuclear palsy and multiple system atrophy: validation of the NNIPPS-Parkinson plus scale","volume":"6","author":"Payan","year":"2011","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.parkreldis.2016.04.014_bib14","first-page":"1","article-title":"Relative importance for linear regression in R: the package relaimpo","volume":"17","author":"Gromping","year":"2006","journal-title":"J.\u00a0Stat. Softw."},{"key":"10.1016\/j.parkreldis.2016.04.014_bib15","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J.\u00a0R. Stat. Soc. Ser. B Stat. Methodol."},{"issue":"3","key":"10.1016\/j.parkreldis.2016.04.014_bib16","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.parkreldis.2011.10.013","article-title":"Rates of brain atrophy and clinical decline over 6 and 12-month intervals in PSP: determining sample size for treatment trials","volume":"18","author":"Whitwell","year":"2012","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.parkreldis.2016.04.014_bib17","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/mds.20707","article-title":"Characterizing behavioral and cognitive dysexecutive changes in progressive supranuclear palsy","volume":"21","author":"Millar","year":"2006","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2016.04.014_bib18","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1093\/brain\/awq158","article-title":"Cognitive impairment in patients with multiple system atrophy and progressive supranuclear palsy","volume":"133","author":"Brown","year":"2010","journal-title":"Brain"},{"key":"10.1016\/j.parkreldis.2016.04.014_bib19","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1093\/arclin\/acs098","article-title":"Executive dysfunction is the primary cognitive impairment in progressive supranuclear palsy","volume":"28","author":"Gerstenecker","year":"2013","journal-title":"Arch. Clin. Neuropsychol."},{"key":"10.1016\/j.parkreldis.2016.04.014_bib20","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1212\/WNL.47.5.1184","article-title":"Neuropsychiatric aspects of progressive supranuclear palsy","volume":"47","author":"Litvan","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2016.04.014_bib21","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1002\/mds.22794","article-title":"A\u00a0comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy","volume":"25","author":"Schrag","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2016.04.014_bib22","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/mds.21393","article-title":"Genetic variation at the tau locus and clinical syndromes associated with progressive supranuclear palsy","volume":"22","author":"Williams","year":"2007","journal-title":"Mov. Disord."}],"container-title":["Parkinsonism & Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802016301183?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802016301183?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T22:15:14Z","timestamp":1718489714000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802016301183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":22,"alternative-id":["S1353802016301183"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2016.04.014","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2016.04.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}